Literature DB >> 11385265

Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay.

D Dressler1, G Dirnberger.   

Abstract

Antibodies against botulinum toxin (BT) are currently best detected by the mouse diaphragm assay (MDA). Nevertheless, the MDA still has disadvantages, so that an immunoprecipitation assay (IPA) was introduced recently. We sought to compare the results of both tests. 33 samples from patients with cervical dystonia and complete or partial BT therapy failure underwent blinded simultaneous IPA and MDA testing. 27 (82%) samples showed concordant results, 17 (52%) being positive and 10 (30%) negative for both IPA and MDA resulting in a significant association of the dichotomous test results (Fisher's exact test, p < 0.01). The other six samples (18%) showed discordant results, all being IPA-negative and MDA-positive. This excess of MDA-positive results was also significant (Sign rank test, p = 0.03). IPA and MDA results showed a very strong and significant qualitative and quantitative association. The IPA seems to be less sensitive than the MDA for detection of low BT-AB titres, but the clinical relevance of this still needs to be established. Since the IPA is simpler, faster and cheaper than the MDA and avoids sacrifice of animals, it could become the preferred BT-AB test. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11385265     DOI: 10.1159/000052139

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  10 in total

Review 1.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

2.  New approach for the rational selection of markers to identify botulinum toxins.

Authors:  Osnat Rosen; Liron Feldberg; Eyal Dor; Ran Zichel
Journal:  Arch Toxicol       Date:  2021-02-10       Impact factor: 5.153

3.  Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity.

Authors:  Kerstin Müller; Eilhard Mix; Fereshte Adib Saberi; Dirk Dressler; Reiner Benecke
Journal:  J Neural Transm (Vienna)       Date:  2009-04-08       Impact factor: 3.575

4.  [Proof of botulinum toxin antibodies with the Extensor Digitorum Brevis Test].

Authors:  A Bachhuber; A Wagner; G Reichel; M Doberenz; A Stenner; W Hermann
Journal:  Nervenarzt       Date:  2008-08       Impact factor: 1.214

Review 5.  [Antibody-induced failure of botulinum toxin therapy].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2003-12       Impact factor: 1.214

Review 6.  Clinical relevance of botulinum toxin immunogenicity.

Authors:  Reiner Benecke
Journal:  BioDrugs       Date:  2012-04-01       Impact factor: 5.807

7.  Development of an Innovative in Vitro Potency Assay for Anti-Botulinum Antitoxins.

Authors:  Osnat Rosen; Eyal Ozeri; Ada Barnea; Alon Ben David; Ran Zichel
Journal:  Toxins (Basel)       Date:  2016-09-24       Impact factor: 4.546

8.  Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia.

Authors:  Dirk Dressler; Sebastian Paus; Andrea Seitzinger; Bernd Gebhardt; Andreas Kupsch
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-05-18       Impact factor: 10.154

9.  Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports.

Authors:  Sebastian Torres; Mark Hamilton; Elena Sanches; Polina Starovatova; Elena Gubanova; Tatiana Reshetnikova
Journal:  Clin Cosmet Investig Dermatol       Date:  2013-12-18

10.  Highly Specific Monoclonal Antibody Targeting the Botulinum Neurotoxin Type E Exposed SNAP-25 Neoepitope.

Authors:  Adva Mechaly; Eran Diamant; Ron Alcalay; Alon Ben David; Eyal Dor; Amram Torgeman; Ada Barnea; Meni Girshengorn; Lilach Levin; Eyal Epstein; Ariel Tennenhouse; Sarel J Fleishman; Ran Zichel; Ohad Mazor
Journal:  Antibodies (Basel)       Date:  2022-03-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.